Divining what President Trump is thinking is not always an easy task, but biotech executive John Crowley believes he may have some insight — at least when it comes to Trump’s views on the Food and Drug Administration.

Earlier this week, Trump gave a major speech vowing to “slash restraints” at the FDA to speed drug approvals and he has previously promised to get rid 75 percent to 80 percent of regulations. Crowley is no mind reader, but after a private meeting with Trump at the White House before the speech, he came away with the impression that the president does not really want to unravel the FDA.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • After a “private meeting” Prime Minister May also thought she had an idea that Our Dear Leader would be supportive. Good luck with that.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy